Table 3 Number of divergent phenotypes per individual in the sample.

From: Pharmacogenetic genotype and phenotype frequencies in a large Danish population-based case-cohort sample

Number of divergent phenotypes

Total sample (N = 77,684)

SMD case-cohort (N = 51,464)

Population cohort (N = 26,220)

N

(%)

N

(%)

N

(%)

0

21

(0.03)

12

(0.02)

9

(0.03)

1

2014

(2.6)

1 348

(2.6)

666

(2.5)

2

11,764

(15.1)

7804

(15.2)

3960

(15.1)

3

25,623

(33.0)

16,931

(32.9)

8692

(33.2)

4

24,226

(31.2)

16 046

(31.2)

8180

(31.2)

5

11,294

(14.5)

7513

(14.6)

3781

(14.4)

6

2461

(3.2)

1628

(3.2)

833

(3.2)

7–9a

281

(0.4)

182

(0.4)

99

(0.4)

  1. SMD severe mental disorders, DPYD dihydropyrimidine dehydrogenase, GAS gene activity score, FVL factor V Leiden, TPMT thiopurine methyltransferase, UGT1A1 UDP-glucuronosyltransferase 1A1, VKORC1 vitamin K epoxide reductase complex 1.
  2. aNumbers in this row were grouped to prevent showing data <5.
  3. Ten phenotypes (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, DPYD, FVL, TPMT, UGT1A1, VKORC1) are included. Divergent phenotypes are considered phenotypes that are not extensive metabolizers, homozygote expressers, DPYD GAS 2, or wild-type carriers.
Back to article page